Biofrontera Q2 revenue rises on higher volume, pricing

Biofrontera

13/08/2026 14:01

Overview
U.S. biopharmaceutical firm's Q2 revenue grew 33% yr/yr, driven by higher unit volume and pricing
Net loss for Q2 narrowed to $0.6 mln from $5.3 mln a year ago
Adjusted EBITDA for Q2 improved to near breakeven, reflecting lower costs post-strategic transaction

Outlook
Company expects to launch Ameluz for sBCC in Q1 2027 if approved
Biofrontera does not expect ITC order to impact full-year 2026 revenue goals
Company says it is making progress towards cash flow breakeven in 2026

Result Drivers
PRICE AND VOLUME - Co said revenue growth was driven by higher unit volume and a price increase
COST STRUCTURE CHANGE - Gross margin improvement attributed to new Ameluz cost structure after strategic transaction
LITIGATION COSTS DOWN - Operating expenses declined due to lower litigation-related legal fees

Company press release: ID:nGNXbnk0BK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$12 mln
$10.50 mln (2 Analysts)
Q2 Loss Per Share
 
$0.05
 
Q2 Net Loss
 
$600,000
 
Q2 Adjusted EBITDA
Meet
-$200,000
-$200,000 (1 Analyst)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 380% above its August 12 closing price of $1.25
The stock recently traded at 513 times the next 12-month earnings vs. a P/E of 48 three months ago

Reuters Recommended Reads
Aug 13 - Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
Aug 10 - Biohaven Q2 net loss narrows on lower R&D spend

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)